This content is machine translated MASH Pharmacotherapies as “Game Changers”—What Are the Upcoming Challenges? Two drug therapy options—semaglutide (s.c.) and resmetirom (oral)—are now approved in the EU and the U.S. for the treatment of MASH. This is a major breakthrough, especially since, for a...…
View Post 6 min This content is machine translated MASLD/MASH: lifestyle, pharmacotherapy, bariatric procedures Addressing metabolic drivers and counteracting fibrosis Steatotic liver diseases that are not associated with alcohol consumption are now referred to as metabolic steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH). There is now no need...…
View Post 8 min This content is machine translated Obesity treatment: new study data Incretin mimetics for comorbidities such as type 2 diabetes, ASCVD, HF, OSAS Lifestyle-related measures are the basic framework in the treatment of overweight and obesity. However, in order to achieve and maintain the target weight, accompanying pharmacological or surgical measures are usually...…
View Post 5 min This content is machine translated Heterogeneous safety profiles for dermatological and endocrine AEs Not all GLP1-RA are the same GLP1-RA effectively improve blood glucose, weight and cardiovascular parameters, but are increasingly in focus due to possible additional side effects such as alopecia and neuropsychiatric effects. A large real-world analysis...…
View Post 14 min This content is machine translated Heart failure and type 2 diabetes Oral semaglutide and cardiac decompensation in type 2 diabetes The secondary analysis of the SOUL trial from JAMA Internal Medicine 2026 proves for the first time: Oral semaglutide significantly reduces heart failure events in patients with pre-existing HFpEF –...…
View Post 6 min This content is machine translated Incretin mimetics for obesity and prediabetes Liraglutide, semaglutide and tirzepatide: considerable evidence base Weight reduction is an important therapeutic measure in diabetes prevention. Prediabetes is characterized by elevated fasting blood sugar and/or impaired glucose tolerance, but not yet manifest diabetes. In obese people,...…
View Post 4 min This content is machine translated Semaglutide and tirzepatide in HFpEF and T2D/obesity Prospect of improved cardiovascular prognosis Patients suffering from heart failure with preserved ejection fraction (HFpEF) are very often also affected by cardiometabolic comorbidities such as obesity and type 2 diabetes. Although previous randomized trials suggest...…
View Post 6 min This content is machine translated MASLD often goes unnoticed and is underestimated Think tank for improving the supply situation Metabolic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), can lead to serious complications. Non-invasive diagnostics and AI-supported screening have the potential to facilitate early detection in...…
View Post 6 min This content is machine translated Recognize CKD early and avoid dialysis Screen diabetics and hypertensive patients regularly and use modern therapies High blood pressure and diabetes are the main causes of CKD – early diagnosis and treatment can reduce the risk of kidney failure and cardiorenal complications. Regular screening of these...…
View Post 4 min This content is machine translated Psoriasis and metabolic comorbidities: new study data GLP-1RAs showed a valuable dual benefit GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients...…
View Post 3 min This content is machine translated Development of a quintuple agonist New strategy in the fight against obesity and T2D The treatment of obesity and type 2 diabetes is increasingly shifting to newer incretin drugs, including GLP1 receptor agonists (single agonists such as semaglutide) and GIP- and GLP1-RA (dual agonists...…
